Piper Jaffray Companies Reiterates “Hold” Rating for AMAG Pharmaceuticals (AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG)‘s stock had its “hold” rating reissued by Piper Jaffray Companies in a research report issued to clients and investors on Thursday. They currently have a $15.00 target price on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price target indicates a potential upside of 13.21% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. B. Riley assumed coverage on shares of AMAG Pharmaceuticals in a research report on Thursday, December 7th. They set a “neutral” rating and a $16.00 price objective for the company. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Morgan Stanley reduced their price objective on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, November 3rd. Finally, ValuEngine upgraded shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Twelve research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $21.00.

AMAG Pharmaceuticals (AMAG) traded down $0.70 during trading hours on Thursday, reaching $13.25. 797,989 shares of the company’s stock were exchanged, compared to its average volume of 825,392. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48. The firm has a market capitalization of $467.57, a PE ratio of -2.18 and a beta of 0.79. AMAG Pharmaceuticals has a 52 week low of $11.93 and a 52 week high of $25.20.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.57 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $1.61. AMAG Pharmaceuticals had a negative net margin of 35.35% and a negative return on equity of 0.64%. equities research analysts predict that AMAG Pharmaceuticals will post -4.17 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Hartford Investment Management Co. acquired a new stake in shares of AMAG Pharmaceuticals in the third quarter valued at about $186,000. 361 Capital LLC acquired a new stake in shares of AMAG Pharmaceuticals in the third quarter valued at about $197,000. Cubist Systematic Strategies LLC purchased a new stake in shares of AMAG Pharmaceuticals in the third quarter valued at about $197,000. Aperio Group LLC purchased a new stake in shares of AMAG Pharmaceuticals in the third quarter valued at about $198,000. Finally, Municipal Employees Retirement System of Michigan grew its holdings in shares of AMAG Pharmaceuticals by 58.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 13,150 shares of the specialty pharmaceutical company’s stock valued at $243,000 after purchasing an additional 4,870 shares during the period.

TRADEMARK VIOLATION NOTICE: “Piper Jaffray Companies Reiterates “Hold” Rating for AMAG Pharmaceuticals (AMAG)” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://stocknewstimes.com/2018/01/19/piper-jaffray-companies-reiterates-hold-rating-for-amag-pharmaceuticals-amag.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply